Mengis Capital Management Inc. cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 29,045 shares of the company’s stock after selling 600 shares during the period. Johnson & Johnson accounts for about 2.5% of Mengis Capital Management Inc.’s investment portfolio, making the stock its 9th biggest holding. Mengis Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,776,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its stake in Johnson & Johnson by 0.4% during the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after buying an additional 130,437 shares during the last quarter. Sigma Planning Corp raised its stake in Johnson & Johnson by 3.4% during the third quarter. Sigma Planning Corp now owns 80,724 shares of the company’s stock valued at $10,495,000 after buying an additional 2,620 shares during the last quarter. Wellington Shields Capital Management LLC raised its stake in Johnson & Johnson by 9.2% during the third quarter. Wellington Shields Capital Management LLC now owns 56,220 shares of the company’s stock valued at $7,309,000 after buying an additional 4,725 shares during the last quarter. Wellington Shields & Co. LLC raised its stake in Johnson & Johnson by 1.0% during the third quarter. Wellington Shields & Co. LLC now owns 43,047 shares of the company’s stock valued at $5,597,000 after buying an additional 415 shares during the last quarter. Finally, Massey Quick Simon & CO. LLC raised its stake in Johnson & Johnson by 2.0% during the third quarter. Massey Quick Simon & CO. LLC now owns 182,519 shares of the company’s stock valued at $23,729,000 after buying an additional 3,530 shares during the last quarter. Institutional investors own 65.70% of the company’s stock.

A number of research analysts have issued reports on JNJ shares. Citigroup lifted their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. Jefferies Group lifted their price objective on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price target for the company in a research note on Wednesday, December 20th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Finally, Barclays boosted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $146.16.

Shares of Johnson & Johnson (JNJ) opened at $129.53 on Monday. The company has a market capitalization of $347,980.00, a price-to-earnings ratio of 332.13, a P/E/G ratio of 2.33 and a beta of 0.74. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1 year low of $114.23 and a 1 year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. The company had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. Johnson & Johnson had a return on equity of 27.80% and a net margin of 1.70%. Johnson & Johnson’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.58 earnings per share. equities analysts forecast that Johnson & Johnson will post 8.08 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.59%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 861.54%.

TRADEMARK VIOLATION WARNING: “Mengis Capital Management Inc. Reduces Position in Johnson & Johnson (JNJ)” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2018/02/12/mengis-capital-management-inc-reduces-position-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.